(Q34821530)

English

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 August 2017

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients (English)

1 reference

Europe PubMed Central

4 August 2017

0 references

1 reference

based on heuristic

inferred from title

François Bricaire

11

object named as

François Bricaire

0 references

Christine Katlama

13

object named as

Christine Katlama

0 references

Anne-Geneviève Marcelin

1

object named as

Anne-Geneviève Marcelin

1 reference

Europe PubMed Central

4 August 2017

Dominique Costagliola

12

object named as

Dominique Costagliola

0 references

Gilles Peytavin

14

object named as

Gilles Peytavin

1 reference

Europe PubMed Central

4 August 2017

10

object named as

Philippe Bossi

1 reference

Europe PubMed Central

4 August 2017

9

object named as

Anne Simon

1 reference

Europe PubMed Central

4 August 2017

Constance Delaugerre

3

object named as

Constance Delaugerre

1 reference

Europe PubMed Central

4 August 2017

8

object named as

Marc Wirden

1 reference

Europe PubMed Central

4 August 2017

Manuela Bonmarchand

7

object named as

Manuela Bonmarchand

1 reference

Europe PubMed Central

4 August 2017

2

object named as

Claire Lamotte

1 reference

Europe PubMed Central

4 August 2017

4

object named as

Nadine Ktorza

1 reference

Europe PubMed Central

4 August 2017

author name string

Hocine Ait Mohand

5

1 reference

Europe PubMed Central

4 August 2017

Raquel Cacace

6

1 reference

Europe PubMed Central

4 August 2017

Vincent Calvez

15

1 reference

Europe PubMed Central

4 August 2017

Genophar Study Group

16

1 reference

Europe PubMed Central

4 August 2017

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

4 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

4 August 2017

47

1 reference

Europe PubMed Central

4 August 2017

2

1 reference

Europe PubMed Central

4 August 2017

594-600

1 reference

Europe PubMed Central

4 August 2017

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

8 July 2018

Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

26 October 2018

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

26 October 2018

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

26 October 2018

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=151735

26 October 2018

The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals

1 reference

https://pubmed.ncbi.nlm.nih.gov/12543665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/12543665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Therapeutic management of HIV-infected subjects. Report of the expert group under the direction of Prof. J.F. Delfraissy, 1999]

1 reference

https://pubmed.ncbi.nlm.nih.gov/12543665

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.47.2.594-600.2003

1 reference

Europe PubMed Central

4 August 2017

PMC publication ID

1 reference

Europe PubMed Central

4 August 2017

1 reference

Europe PubMed Central

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34821530&oldid=1950415722"